Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Source: View publication →
Lenvatinib combined with pembrolizumab demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival, overall survival, and objective response rate compared to sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CLEAR trial established the potent multikinase VEGFR inhibitor lenvatinib combined with the PD-1 inhibitor pembrolizumab as a highly effective standard-of-care first-line treatment for advanced clear-cell renal cell carcinoma. The unprecedented median PFS of nearly two years and an ORR exceeding 70% represent a major advance in controlling disease burden across all IMDC prognostic risk groups.
Historical Context
For over a decade, single-agent VEGFR tyrosine kinase inhibitors (TKIs) like sunitinib and pazopanib were the standard first-line therapies for advanced renal cell carcinoma. The landscape subsequently shifted towards combination therapies, first with dual immunotherapy (nivolumab plus ipilimumab) and then with IO-TKI combinations (e.g., axitinib plus pembrolizumab, cabozantinib plus nivolumab). The CLEAR trial added to this new era by evaluating the combination of pembrolizumab with lenvatinib, a TKI known for its high single-agent potency and multikinase profile (inhibiting VEGFR 1-3, FGFR 1-4, PDGFR alpha, RET, and KIT), seeking to maximize anti-tumor response and extend survival outcomes over the sunitinib standard.
Guided Discussion
High-yield insights from every perspective
What is the mechanistic rationale behind combining a multi-kinase inhibitor like lenvatinib with an immune checkpoint inhibitor like pembrolizumab in advanced clear-cell renal cell carcinoma?
Key Response
Students need to understand that clear-cell RCC is highly vascularized due to VHL mutations leading to HIF upregulation and VEGF production. Lenvatinib blocks angiogenesis (VEGFR inhibition), which not only starves the tumor of blood supply but also normalizes the tumor microenvironment by reducing immunosuppressive cells like MDSCs and regulatory T cells. This creates a more permissive environment that enhances the efficacy of T cells activated by the anti-PD-1 antibody pembrolizumab.
A patient receiving lenvatinib plus pembrolizumab for advanced RCC presents with grade 3 diarrhea. How do you clinically differentiate whether this is a TKI-related toxicity or an immune-related adverse event (irAE) from pembrolizumab, and how does this affect your immediate management?
Key Response
Residents frequently manage treatment toxicities. Differentiating TKI diarrhea from IO colitis is critical. TKI-related diarrhea is typically secretory and resolves relatively quickly (within 24-72 hours) after holding the TKI. Immune-mediated colitis is inflammatory, persists despite holding the drug, and requires systemic corticosteroids. The standard initial approach is to hold the lenvatinib; if symptoms rapidly improve, it is likely TKI-related. If symptoms persist or worsen, an irAE should be suspected, prompting workup (e.g., endoscopy) and initiation of steroids.
With the CLEAR trial establishing lenvatinib plus pembrolizumab as a highly active first-line option, how do you select between an IO-TKI combination (like lenvatinib/pembrolizumab) versus an IO-IO combination (like nivolumab/ipilimumab) for a newly diagnosed patient with intermediate-risk advanced RCC?
Key Response
Fellows must navigate overlapping indications. IO-IO (nivo/ipi) offers a chance at durable, treatment-free complete responses and avoids chronic TKI toxicity, but carries a higher risk of early disease progression (primary refractoriness). IO-TKI (lenva/pembro) provides a higher objective response rate (71%) and longer median PFS, making it ideal for symptomatic patients or those with high disease burden who need rapid disease control, though it commits the patient to continuous TKI therapy with chronic low-grade toxicities.
The CLEAR trial used a starting dose of 20 mg daily for lenvatinib, which resulted in a high rate of dose interruptions and reductions (nearly 70% of patients). In real-world practice, does starting at a lower dose (e.g., 14 mg) compromise the robust efficacy seen in this trial, or does it optimize the therapeutic index and patient adherence?
Key Response
Attendings focus on real-world applicability and quality of life. While the trial's overall survival benefit was proven at the 20 mg starting dose, the toxicity profile often leads to early treatment fatigue or discontinuation in clinical practice. The discussion centers on whether 'starting high and reducing' is necessary to achieve the rapid cytoreduction observed in the trial, versus the pragmatic approach of dose escalation to prioritize patient tolerance, knowing that drug exposure and target saturation may differ at lower doses.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CLEAR trial utilized sunitinib as the active comparator. Given the rapid evolution of standard-of-care therapies during the trial's enrollment, how does the choice of control arm and the subsequent lines of therapy received by patients progressing on sunitinib impact the interpretation of the overall survival benefit?
Key Response
Methodologists must evaluate trial design validity over time. While sunitinib was a valid control when the trial began, IO-based combinations rapidly became standard. The true test of OS benefit requires analyzing whether the sunitinib arm patients received effective subsequent IO therapy (crossover effect). If post-progression IO use was low in the control arm, the survival benefit of lenvatinib/pembrolizumab might reflect the advantage of receiving IO at all, rather than the superiority of this specific upfront combination over sequential optimal therapy.
The CLEAR trial was designed as a three-arm study, testing both lenvatinib+pembrolizumab and lenvatinib+everolimus against sunitinib. As an editor, how do you critically evaluate the study's alpha-spending plan and multiplicity adjustments, particularly given that the everolimus arm failed to show an OS benefit?
Key Response
Editors must scrutinize statistical rigor in multi-arm trials. The total alpha (type I error rate) had to be allocated between the two experimental arms. A tough reviewer would flag the hierarchical testing sequence to ensure that the success of the pembrolizumab arm wasn't statistically inflated and that the failure of the everolimus arm on OS did not compromise the power or validity of the primary comparisons, ensuring that the trial's positive conclusions are robust against multiple testing penalties.
Based on the unprecedented median PFS of 23.9 months and high ORR reported in the CLEAR trial, should lenvatinib plus pembrolizumab be designated as the single 'preferred' first-line regimen in NCCN/EAU guidelines, or should it remain one of several Category 1 IO-TKI options alongside axitinib/pembrolizumab and cabozantinib/nivolumab?
Key Response
Guideline committees must decide how to rank therapies in the absence of head-to-head trials. While CLEAR showed numerically the longest PFS and highest ORR among modern IO-TKI trials, cross-trial comparisons are fraught with confounding due to differing patient populations and risk distributions. Currently, guidelines list multiple IO-TKI combinations as Category 1. The committee must weigh if the magnitude of benefit in CLEAR is strong enough to supersede the methodological limitations of cross-trial comparison to elevate it above other standard-of-care regimens.
Clinical Landscape
Noteworthy Related Trials
CheckMate 214
Tested
Nivolumab plus Ipilimumab
Population
Patients with previously untreated advanced renal cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival, objective response rate, and progression-free survival
KEYNOTE-426
Tested
Pembrolizumab plus Axitinib
Population
Patients with previously untreated advanced clear-cell renal cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival and progression-free survival
CheckMate 9ER
Tested
Nivolumab plus Cabozantinib
Population
Patients with previously untreated advanced clear-cell renal cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis